- Home
- PHAT vs SLDB Comparison
PHAT vs SLDB Comparison
Compare PHAT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- SLDB
- Stock Information
- Founded
- PHAT 2018
- SLDB 2013
- Country
- PHAT United States
- SLDB United States
- Employees
- PHAT N/A
- SLDB N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHAT Health Care
- SLDB Health Care
- Exchange
- PHAT Nasdaq
- SLDB Nasdaq
- Market Cap
- PHAT 423.4M
- SLDB 366.2M
- IPO Year
- PHAT 2019
- SLDB 2018
- Fundamental
- Price
- PHAT $5.12
- SLDB $3.45
- Analyst Decision
- PHAT Strong Buy
- SLDB Strong Buy
- Analyst Count
- PHAT 4
- SLDB 10
- Target Price
- PHAT $23.00
- SLDB $18.10
- AVG Volume (30 Days)
- PHAT 1.5M
- SLDB 1.2M
- Earning Date
- PHAT 03-06-2025
- SLDB 03-06-2025
- Dividend Yield
- PHAT N/A
- SLDB N/A
- EPS Growth
- PHAT N/A
- SLDB N/A
- EPS
- PHAT N/A
- SLDB N/A
- Revenue
- PHAT $55,252,000.00
- SLDB N/A
- Revenue This Year
- PHAT $202.16
- SLDB N/A
- Revenue Next Year
- PHAT $113.86
- SLDB $717.65
- P/E Ratio
- PHAT N/A
- SLDB N/A
- Revenue Growth
- PHAT 8001.47
- SLDB N/A
- 52 Week Low
- PHAT $4.07
- SLDB $2.88
- 52 Week High
- PHAT $19.71
- SLDB $12.95
- Technical
- Relative Strength Index (RSI)
- PHAT 41.95
- SLDB 32.52
- Support Level
- PHAT $6.03
- SLDB $4.12
- Resistance Level
- PHAT $6.89
- SLDB $4.44
- Average True Range (ATR)
- PHAT 0.58
- SLDB 0.37
- MACD
- PHAT 0.05
- SLDB -0.20
- Stochastic Oscillator
- PHAT 37.23
- SLDB 0.87
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.